| Title: |
Antisense oligonucleotides targeting mutant Ataxin-7 restore visual function in a mouse model of spinocerebellar ataxia type 7 |
| Authors: |
Niu, Chenchen; Prakash, Thazah P; Kim, Aneeza; Quach, John L; Huryn, Laryssa A; Yang, Yuechen; Lopez, Edith; Jazayeri, Ali; Hung, Gene; Sopher, Bryce L; Brooks, Brian P; Swayze, Eric E; Bennett, C Frank; La Spada, Albert R |
| Source: |
Science Translational Medicine, vol 10, iss 465 |
| Publisher Information: |
eScholarship, University of California |
| Publication Year: |
2018 |
| Collection: |
University of California: eScholarship |
| Subject Terms: |
Biomedical and Clinical Sciences; Ophthalmology and Optometry; Rare Diseases; Genetics; Neurosciences; Neurodegenerative; Eye Disease and Disorders of Vision; Orphan Drug; Brain Disorders; Eye; Neurological; Animals; Ataxin-7; Chromatin Assembly and Disassembly; Disease Models; Animal; Disease Progression; Epigenesis; Genetic; Gene Expression Regulation; Humans; Intravitreal Injections; Mice; Mutant Proteins; Oligonucleotides; Antisense; Peptides; Phenotype; Photoreceptor Cells; Vertebrate |
| Description: |
Spinocerebellar ataxia type 7 (SCA7) is an autosomal dominant neurodegenerative disorder characterized by cerebellar and retinal degeneration, and is caused by a CAG-polyglutamine repeat expansion in the ATAXIN-7 gene. Patients with SCA7 develop progressive cone-rod dystrophy, typically resulting in blindness. Antisense oligonucleotides (ASOs) are single-stranded chemically modified nucleic acids designed to mediate the destruction, prevent the translation, or modify the processing of targeted RNAs. Here, we evaluated ASOs as treatments for SCA7 retinal degeneration in representative mouse models of the disease after injection into the vitreous humor of the eye. Using Ataxin-7 aggregation, visual function, retinal histopathology, gene expression, and epigenetic dysregulation as outcome measures, we found that ASO-mediated Ataxin-7 knockdown yielded improvements in treated SCA7 mice. In SCA7 mice with retinal disease, intravitreal injection of Ataxin-7 ASOs also improved visual function despite initiating treatment after symptom onset. Using color fundus photography and autofluorescence imaging, we also determined the nature of retinal degeneration in human SCA7 patients. We observed variable disease severity and cataloged rapidly progressive retinal degeneration. Given the accessibility of neural retina, availability of objective, quantitative readouts for monitoring therapeutic response, and the rapid disease progression in SCA7, ASOs targeting ATAXIN-7 might represent a viable treatment for SCA7 retinal degeneration. |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
unknown |
| Relation: |
qt7g87r2bc; https://escholarship.org/uc/item/7g87r2bc; https://escholarship.org/content/qt7g87r2bc/qt7g87r2bc.pdf |
| DOI: |
10.1126/scitranslmed.aap8677 |
| Availability: |
https://escholarship.org/uc/item/7g87r2bc; https://escholarship.org/content/qt7g87r2bc/qt7g87r2bc.pdf; https://doi.org/10.1126/scitranslmed.aap8677 |
| Rights: |
public |
| Accession Number: |
edsbas.7D6ECF94 |
| Database: |
BASE |